CJC-1295 for Health & Longevity

Evidence Review created on 08/06/2026 using AI4L / Opus 5

Also known as: CJC-1295 with DAC, CJC-1295 DAC, DAC:GRF, Tetrasubstituted GRF (1-29), CJC-1295 without DAC, Modified GRF 1-29, Mod GRF 1-29

Motivation

CJC-1295 is a laboratory-made copy of a natural brain hormone that signals the pituitary gland to release growth hormone. It was engineered to lock onto a blood protein so that a single injection keeps working for roughly a week rather than a few minutes. Because growth hormone output falls steadily with age, people focused on body composition and recovery have looked to compounds like this one as a way to nudge that system upward.

A Canadian biotechnology company created the compound in the early 2000s and tested it in healthy volunteers and in people with fat accumulation linked to long-term antiviral treatment. Company-sponsored development was halted after a death during a mid-stage trial, and the compound has never been approved for use anywhere. It has nonetheless spread widely through wellness clinics and online sellers labelling it for research use only.

This review examines what the human and animal evidence shows about CJC-1295: what it does to hormone levels, which benefits and harms have been observed or inferred, and how much of the picture rests on studies of related compounds rather than on CJC-1295 itself.

Benefits - Risks - Protocol - Conclusion

Grokipedia

CJC-1295

The article covers the peptide’s structure as a tetrasubstituted analog of the active fragment of growth hormone-releasing hormone, the albumin-binding modification, and the trial history, and is useful as a fast orientation to the distinction between the drug affinity complex version and the version without it.

Examine

No Examine article exists for CJC-1295. Examine.com covers dietary supplements and nutrients rather than injectable investigational drugs available only on prescription or through research-chemical suppliers, which is the category CJC-1295 falls into.

ConsumerLab

No ConsumerLab article exists for CJC-1295. ConsumerLab tests retail dietary supplements and foods; it does not typically cover prescription or investigational injectable medications, and no CJC-1295 product is sold through the retail supplement channel it audits.

Systematic Reviews

No systematic reviews or meta-analyses for CJC-1295 were found on PubMed as of 06 August 2026.

Mechanism of Action

CJC-1295 is a synthetic analog of the first 29 amino acids of GHRH (growth hormone-releasing hormone, the hypothalamic signal that instructs the pituitary gland to make and release growth hormone). That 1-29 fragment carries essentially all of the biological activity of the full 44-amino-acid hormone. CJC-1295 carries four amino acid substitutions plus a fifth modification at the tail end of the molecule.

Receptor activation. The peptide binds the GHRH receptor on somatotrophs (the growth-hormone-producing cells of the anterior pituitary). This is a G-protein-coupled receptor; binding raises intracellular cAMP (cyclic adenosine monophosphate, a common second messenger inside cells) and activates PKA (protein kinase A, the enzyme that cAMP switches on), which drives both the synthesis of new growth hormone and its release from storage granules.
Resistance to enzymatic breakdown. Native GHRH is cleaved within minutes by DPP-4 (dipeptidyl peptidase-4, an enzyme that clips two amino acids off the front of many peptide hormones). Substituting D-alanine at position 2 blocks that cleavage; substitutions at positions 8, 15, and 27 reduce chemical degradation and improve binding. This tetrasubstituted molecule, on its own, is sold as Modified GRF 1-29 or “CJC-1295 without DAC” (DAC stands for drug affinity complex, the albumin-binding modification described below) and has a half-life of roughly 30 minutes.
The albumin tether. The defining modification is a maleimidopropionamide group added to a lysine at the C-terminal end. After subcutaneous injection this group reacts covalently and irreversibly with a free thiol on cysteine-34 of circulating albumin, the most abundant protein in blood. The peptide then travels as a passenger on a protein with a natural half-life of around three weeks, which is what converts a minutes-long signal into a days-long one (Jetté et al., 2005; this identification work was performed entirely by the research department of ConjuChem, the company that owned and was developing the compound, and that commercial interest applies to essentially the whole primary literature on CJC-1295).
Downstream output. Growth hormone released from the pituitary acts on the liver and peripheral tissues to generate IGF-1 (insulin-like growth factor 1, the hormone that carries out most of growth hormone’s tissue-building effects). IGF-1 in turn feeds back to suppress GHRH and stimulate somatostatin, the brake on growth hormone release. This intact feedback loop is the mechanistic argument for why a secretagogue is considered safer than injecting growth hormone directly.
Preserved pulsatility. A competing mechanistic concern was that continuous receptor stimulation would flatten the natural pulses of growth hormone secretion, since pulsatility itself is thought to matter for several downstream effects. Direct measurement contradicted this: overnight sampling one week after a single injection showed pulse frequency and pulse amplitude unchanged, with the entire increase in output coming from a 7.5-fold rise in trough levels between pulses (Ionescu & Frohman, 2006). The opposing view — that a permanently elevated trough is itself unphysiological, because no healthy human maintains continuous growth hormone exposure — has not been resolved by any long-term study.

Key pharmacological properties of the compound:

Half-life: 5.8–8.1 days for the drug affinity complex form in healthy adults; approximately 30 minutes for the version without the albumin tether; approximately 7 minutes for native GHRH.
Selectivity: Selective for the GHRH receptor. It has no meaningful activity at the growth hormone secretagogue receptor (the ghrelin receptor targeted by growth hormone-releasing peptides such as ipamorelin and by MK-677), which is why it does not, on its own, stimulate appetite, prolactin, or cortisol.
Tissue distribution: Once bound to albumin, distribution is essentially confined to plasma and interstitial fluid, with a volume of distribution approximating that of albumin itself. The functional target is the anterior pituitary, which sits outside the blood-brain barrier and is therefore accessible to a circulating peptide.
Metabolism and elimination: Cleared by ordinary proteolytic catabolism of the albumin conjugate rather than by any hepatic enzyme system. It is not a substrate, inhibitor, or inducer of the cytochrome P450 enzymes (the liver enzyme family responsible for most small-molecule drug interactions), so classical pharmacokinetic drug interactions are not expected. Elimination therefore tracks albumin turnover, which is slowed in liver disease and accelerated in protein-losing states and in critical illness.

Historical Context & Evolution

Original intended use. CJC-1295 was developed by ConjuChem Biotechnologies of Montreal in the early 2000s as a pharmaceutical treatment, not as a wellness compound. The company’s platform technology was the drug affinity complex — a way of covalently tethering short-lived peptide drugs to albumin — and CJC-1295 was the growth hormone application of that platform. The named target indications were growth hormone deficiency and the visceral obesity and lipodystrophy (a redistribution of body fat toward the abdomen and away from the limbs and face) seen in people on long-term treatment for HIV (human immunodeficiency virus, the virus that causes acquired immune deficiency syndrome).
What the original research actually found. Two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21–61 established the core pharmacology: single subcutaneous injections raised mean plasma growth hormone 2- to 10-fold for six days or longer and IGF-1 1.5- to 3-fold for 9–11 days, with IGF-1 remaining above baseline for up to 28 days after repeated dosing and clear evidence of accumulation. No serious adverse reactions were reported, and 30 and 60 µg/kg were singled out as the best-tolerated doses (Teichman et al., 2006). This work was sponsored by ConjuChem and several authors were company personnel or paid consultants. Parallel animal work showed that once-daily dosing normalized both growth and body composition in mice engineered to lack GHRH entirely, and that dosing every 48 or 72 hours was progressively less effective (Alba et al., 2006).
Why development stopped. A multicentre randomized placebo-controlled phase 2 trial in people with HIV-associated visceral obesity, NCT00267527, was halted by the sponsor in July 2006 after a participant at an Argentine site died. Contemporaneous reporting described a fatal cardiac event a few hours after an eleventh weekly injection. The sponsor’s position was that the death was unlikely to be drug-related; the counter-argument, raised repeatedly since, is that the compound is known to cause fluid retention and expanded plasma volume, which is a biologically plausible route to a cardiac event. No adjudication was ever published, and the trial record was closed as terminated. Both readings remain defensible on the public evidence, and a single event in a small trial cannot establish or exclude causation either way.
Why it came to be considered for health optimization. Two things happened after the corporate programme ended. First, a competing GHRH analog, tesamorelin, from Theratechnologies, completed phase 3 trials in the same indication and was approved, demonstrating that the mechanism could deliver reproducible reductions in visceral fat. Second, growth hormone output declines by roughly 15% per decade after early adulthood, which made growth hormone-releasing agents attractive to a longevity-oriented audience looking for a way to restore an age-declining signal without injecting the hormone itself. Because CJC-1295 had a published human pharmacology profile, an unusually convenient once- or twice-weekly schedule, and no patent holder actively policing supply, it moved into the gray market. Documented forum use for fat loss, muscle gain, skin quality, sleep, and injury healing was already being described in the research literature within a decade (Van Hout & Hearne, 2016).
How the scientific position has moved, and what remains open. The mainstream endocrine position is that growth hormone-axis intervention in adults without documented deficiency is unproven and carries metabolic and oncological uncertainty. That position hardened after several high-profile growth hormone longevity clinics were prosecuted in the 2000s, and it is a genuine reading of the evidence rather than a merely political one. What changed on the other side is that the visceral fat and lipid effects of a GHRH analog were confirmed in more than 800 randomized participants, that a randomized trial found cognitive benefit from a GHRH analog in older adults, and that the distinction between injecting growth hormone and stimulating its release under intact feedback control became better characterized. It is also worth noting that the current consensus is formed by professional bodies whose members treat diagnosed pituitary disease and are reimbursed for that work, while the countervailing enthusiasm comes from clinics and suppliers who sell the compounds; neither side’s position should be read as disinterested. What has not changed is that CJC-1295 itself has no completed efficacy trial in any population.

Expected Benefits

A note on how these grades were assigned: only one benefit — the hormone response itself — has been demonstrated for CJC-1295 in randomized human trials. Every other item rests wholly or partly on trials of other GHRH analogs, chiefly tesamorelin, which act on the same receptor by the same mechanism but with different dosing patterns. That extrapolation is explicitly flagged in each annotation and is the reason grades are capped below where the underlying class data alone would place them.

High 🟩 🟩 🟩

Sustained Elevation of Growth Hormone and IGF-1

CJC-1295 reliably and durably raises both growth hormone and IGF-1 in healthy adults. This is the one effect established directly for this compound, in two randomized, placebo-controlled, double-blind ascending-dose trials, and confirmed by a separate overnight sampling study showing that the increase comes from a large rise in baseline (trough) secretion between preserved natural pulses rather than from bigger pulses. A proteomic study in eleven healthy young men found measurable downstream changes in circulating proteins one week after a single injection, indicating that the hormone rise translates into real biological signalling rather than a laboratory artefact (Sackmann-Sala et al., 2009). The important caveat is that raising these two hormones is a surrogate: it is the mechanism by which any benefit would have to occur, not itself an outcome anyone experiences.

Magnitude: Growth hormone rose 2- to 10-fold for six days or more and IGF-1 rose 1.5- to 3-fold for 9–11 days after a single injection, with IGF-1 staying above baseline for up to 28 days after multiple doses; in the pulsatility study, trough growth hormone rose 7.5-fold, mean growth hormone 46%, and IGF-1 45% one week after one injection.

Medium 🟩 🟩

Reduction in Visceral Abdominal Fat

Visceral fat — the metabolically active fat packed around the abdominal organs, as distinct from the fat under the skin — is the tissue most responsive to growth hormone, which drives lipolysis (the breakdown of stored fat) preferentially in that depot. This was the indication CJC-1295 itself was being trialled for when development stopped, so no CJC-1295 outcome data exist. The evidence comes from the same drug class: in a pooled analysis of two phase 3 trials in 806 randomized participants, daily tesamorelin reduced visceral fat while leaving subcutaneous fat essentially untouched, and the reduction was maintained through 52 weeks (Falutz et al., 2010). Those trials were conducted in people with HIV-associated fat accumulation and were funded by the manufacturer, Theratechnologies, so both the population and the sponsorship differ from the situation of a healthy adult using CJC-1295.

Magnitude: A 15.4% treatment effect on visceral fat at 26 weeks and a 17.5% reduction from baseline at 52 weeks with daily tesamorelin, against no meaningful change in subcutaneous fat.

Improvement in Triglycerides and Cholesterol Ratios

Reducing visceral fat and increasing lipolysis shifts several lipid measures in a favourable direction, and this has been measured directly in the class trials rather than merely inferred. In the 412-participant pivotal trial, triglycerides and the ratio of total cholesterol to HDL (high-density lipoprotein, the cholesterol-carrying particle that removes cholesterol from the artery wall) cholesterol both improved significantly against placebo, and total and HDL cholesterol also moved favourably (Falutz et al., 2007). The nuance is that these are manufacturer-sponsored trials in a population with a specific metabolic disturbance, that lipid changes tracked the visceral fat reduction rather than occurring independently of it, and that no trial has tested whether the same shifts occur in a metabolically healthy adult who does not have excess visceral fat to lose.

Magnitude: Triglycerides fell 50 mg/dL with tesamorelin versus a 9 mg/dL rise on placebo; the total-to-HDL cholesterol ratio fell 0.31 versus a 0.21 rise on placebo, a treatment effect of about 12% for triglycerides and 7% for the cholesterol ratio in the pooled phase 3 data.

Reduction in Liver Fat

Fat accumulating inside liver cells — the earliest stage of non-alcoholic fatty liver disease — tracks closely with visceral fat and with insulin resistance, and it is among the metabolic markers a longevity-oriented adult is most likely to be watching. A 12-month randomized, double-blind, placebo-controlled trial measured liver fat directly by magnetic resonance spectroscopy and found that a daily GHRH analog reduced it substantially, with more than a third of treated participants falling below the diagnostic threshold and no deterioration in fasting glucose (Stanley et al., 2019). The proposed mechanism is the same lipolytic action that drives the visceral fat effect, applied to a depot that responds to it. The same qualifications apply as for visceral fat, and one more besides: the trial enrolled 61 participants, ran in people with HIV rather than in metabolically healthy adults, and used tesamorelin daily rather than CJC-1295, for which no liver imaging data exist at all.

Magnitude: A 4.1 percentage point absolute and 37% relative reduction in liver fat fraction over 12 months of daily GHRH analog against placebo, with 35% of treated participants versus 4% on placebo falling below the 5% liver fat threshold.

Low 🟩

Reduction in Total Body Fat with Preserved Lean Mass

The recomposition effect most people are seeking — less fat, same or more muscle — has been measured with a GHRH analog only in one randomized trial in older adults, where 20 weeks of daily dosing reduced percent body fat measured by dual-energy X-ray absorptiometry (Baker et al., 2012). Supporting evidence for CJC-1295 specifically is confined to animal work: in mice lacking GHRH, once-daily CJC-1295 restored both relative lean mass and subcutaneous fat mass to normal. The honest reading is that growth hormone’s well-documented effect on body composition is modest in adults with an intact pituitary, that some of the apparent lean mass gain in growth hormone studies is fluid rather than contractile tissue, and that no controlled study has measured body composition on CJC-1295 in humans at all.

Magnitude: A 7.4% relative reduction in percent body fat over 20 weeks of daily GHRH analog in adults aged 55–87; no human body composition data exist for CJC-1295 itself.

Improved Executive Function in Older Adults

Growth hormone, IGF-1, and GHRH all act on the brain, all decline with age, and all have been implicated in the biology of cognitive aging. A randomized, double-blind, placebo-controlled trial gave 152 adults aged 55–87 — 66 of them with MCI (mild cognitive impairment, the stage of measurable memory or thinking decline that precedes dementia but does not yet interfere with independent living) — a daily GHRH analog or placebo for 20 weeks. The trial found a favourable overall cognitive effect, driven by executive function, with a similar-sized benefit in the healthy and the impaired groups; verbal memory showed only a trend. This is a single trial, the effect on brain chemistry it was designed around has not been replicated in outcome terms, and the compound used was tesamorelin rather than CJC-1295 given on a completely different schedule.

Magnitude: A favourable cognitive composite effect (P = .03, the P value being the probability of seeing a result this large if the treatment did nothing, by intention-to-treat analysis, which counts every randomized participant regardless of whether they finished; P = .002 among those who completed the study) with executive function as the driving domain (P = .005), alongside a 117% rise in IGF-1 that remained within the physiological range.

Enhanced Deep Sleep ⚠️ Conflicted

Growth hormone’s largest natural pulse occurs during slow-wave sleep (the deepest, most restorative stage of sleep), and GHRH is one of the endogenous signals that promotes non-REM (non-rapid eye movement) sleep, so improved deep sleep is one of the most commonly reported subjective effects of this drug class. The controlled human evidence is genuinely divided by sex: pulsatile GHRH increased non-REM sleep and reduced wakefulness during recovery sleep after 40 hours of sleep deprivation in a 48-person study of both sexes (Schüssler et al., 2006), consistent with earlier work in young men. In healthy young women studied under a randomized design controlled for menstrual cycle phase, the same intervention did the opposite: REM (rapid eye movement) sleep fell at the lower dose and stage 4 deep sleep fell at the higher dose (Mathias et al., 2007). Two design differences plausibly account for the divergence: the deprivation study measured recovery sleep and reported no difference between the sexes within that setting, its authors concluding that peptide regulation of recovery sleep differs from that of spontaneous sleep, whereas the sex divergence — deep sleep enhanced in young men, impaired in women — has been demonstrated in ordinary undisturbed sleep. No sleep study has used CJC-1295, and the continuous exposure produced by the albumin-tethered form differs fundamentally from the timed pulses used in these experiments.

Magnitude: Non-REM sleep increased above placebo during recovery sleep after sleep deprivation in mixed-sex participants, while in healthy young women stage 4 sleep decreased after four 50 µg pulses and REM sleep decreased in the first half of the night after four 25 µg pulses.

Speculative 🟨

Accelerated Soft-Tissue and Tendon Repair

Faster healing of tendon, ligament, and muscle injury is among the most common reasons people obtain this compound, on the reasoning that IGF-1 is a central mediator of connective-tissue repair. There are no controlled human studies of CJC-1295 for any healing endpoint. The basis is entirely mechanistic plus animal data on IGF-1 in tissue repair, and clinician-facing reviews of peptides in sports medicine specifically identify this class of claim as one where rigorous human safety and efficacy data are scarce and where the placebo effect, amplified by social media, is a plausible driver of perceived benefit (Mendias & Awan, 2026).

Peripheral Nerve Regeneration

Preclinical work indicates that GHRH analogs promote axonal regrowth after nerve injury, which is why a phase 2 trial of tesamorelin in peripheral nerve injury is running. No human results are available for any GHRH analog on this endpoint and none exist for CJC-1295, so the basis is animal and mechanistic only.

Improved Skin Thickness and Collagen Density

Growth hormone and IGF-1 stimulate dermal fibroblasts and collagen synthesis, and “youthful skin” appears repeatedly in the documented reasons for self-administration. No controlled study of CJC-1295 has measured any skin endpoint; the basis is mechanistic inference from growth hormone biology together with self-reported effects described in online forum research.

Increased Bone Mineral Density

The growth hormone axis drives bone remodelling and is the mechanism behind the skeletal effects seen in growth hormone deficiency and its treatment. Animal work with CJC-1295 showed normalized femur and tibia length in growing GHRH-deficient mice, but bone length in a growing animal says nothing about density in an adult skeleton. No human bone data exist for this compound, and any effect would take one to two years of continuous exposure to detect.

Benefit-Modifying Factors

Baseline IGF-1 and growth hormone status: The lower the starting point, the larger the expected response and the more room there is for benefit. Adults with age-related decline into the lower part of the reference range have the most to gain; someone already in the upper quartile for their age has little headroom and is closer to the range where the risk items in this review begin to matter.
Baseline visceral fat: The visceral fat and lipid benefits were demonstrated in populations selected for excess abdominal fat. Someone lean at the outset has less of the tissue that responds preferentially, and the same intervention should be expected to produce a proportionally smaller effect.
Baseline insulin sensitivity: Growth hormone directly opposes insulin action. An insulin-sensitive person tolerates a rise in growth hormone with little metabolic cost; someone already insulin resistant may find that the glucose penalty offsets the body composition gain.
Body fat and obesity: Obesity independently suppresses both spontaneous and stimulated growth hormone secretion at the pituitary level, so the same dose produces a smaller hormone response in a person with a high body fat percentage — one of the few genuinely counterintuitive dose-response relationships in this area.
Sex-based differences: Women secrete more growth hormone than men but generate less IGF-1 per unit of growth hormone because estrogen induces relative hepatic growth hormone resistance. Oral estrogen — as opposed to transdermal — passes through the liver first and blunts the IGF-1 response substantially more. Analyses of predictors of response to tesamorelin found smaller visceral fat reductions in women than in men, and the sleep effects of GHRH are directionally opposite in the two sexes.
Age: Somatotroph responsiveness to GHRH declines across the lifespan even though the receptor remains functional, so an adult in their sixties or seventies achieves a smaller absolute hormone peak from the same dose than someone in their thirties. This cuts both ways: the older person has more decline to restore but a less responsive pituitary with which to do it, and is simultaneously more susceptible to the fluid-retention and glucose effects at any given dose.
Genetic variation in the growth hormone receptor: The exon 3-deleted variant of GHR (the gene encoding the growth hormone receptor that transmits the hormone’s signal into cells) is carried by a large minority of people and is associated with a more vigorous IGF-1 response to a given growth hormone exposure. Variants in GHRHR (the gene for the pituitary receptor this compound actually binds) and in IGF1R (the gene for the receptor through which IGF-1 acts) would be expected to modify response upstream and downstream respectively, though none of these has been tested prospectively with a GHRH analog.
APOE4 carrier status: APOE4 (a variant of the gene encoding apolipoprotein E, a cholesterol-transport protein in the brain) is the strongest common genetic risk factor for Alzheimer’s disease. It has repeatedly modified the cognitive response to metabolic and hormonal interventions in older adults, so it is a plausible — though untested for this compound — modifier of any cognitive benefit.
Pre-existing pituitary disease: The entire mechanism depends on a pituitary capable of responding. In someone with hypopituitarism (underactivity of the pituitary gland), a resected pituitary, or prior cranial irradiation, a secretagogue has nothing to act on and direct growth hormone replacement is the only mechanism that could work.
Thyroid and adrenal status: Untreated hypothyroidism and glucocorticoid excess (too much cortisol, whether produced by the body or taken as steroid medication) both suppress growth hormone secretion and blunt the response to GHRH, so an unrecognized problem in either axis will make the intervention look ineffective.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Reactions

Local reactions at the subcutaneous injection site — erythema (redness), pruritus (itching), pain, swelling, and occasionally induration (a firm, hardened patch of tissue) or lipohypertrophy (a localized lump of thickened fat tissue from repeated injection at one spot) — are the most frequently reported adverse event with this compound and with the entire GHRH analog class. The mechanism is a combination of local immune response to a foreign peptide, the reconstitution vehicle, and mechanical trauma. Severity is usually mild and self-limiting, and rotation of injection sites reduces it substantially, but the reactions are the single most common reason people discontinue. With gray-market material the picture is worse, because the reaction may be to a contaminant, an endotoxin (an inflammatory fragment of bacterial cell wall that survives sterilization), or a non-sterile diluent rather than to the peptide itself.

Magnitude: The most frequently reported adverse event across the CJC-1295 human trials and the tesamorelin phase 3 programme; in the 412-participant pivotal tesamorelin trial, overall adverse event rates did not differ significantly from placebo but more treated participants than placebo participants withdrew because of an adverse event.

Fluid Retention and Peripheral Edema

Growth hormone causes sodium and water retention through direct effects on the renal tubule and activation of the renin-angiotensin-aldosterone system (the hormonal cascade that controls blood pressure and salt balance). The result is edema (swelling from fluid accumulating in tissues), most often in the ankles, feet, and hands, sometimes with a rise in blood pressure and a rapid apparent weight gain that is water rather than tissue. This is a recognized dose-dependent class effect of growth hormone-axis stimulation, more common in older adults, in women, and in people with any degree of heart or kidney impairment, and it is largely reversible on dose reduction or discontinuation; expert commentary treats it as a known property of CJC-1295 specifically and as the reason the once-weekly high-dose schedule is singled out as concerning. It also carries the specific concern raised after the terminated phase 2 trial: the associated increase in circulating volume is a biologically plausible contributor to cardiac strain in someone with underlying coronary disease.

Magnitude: Not quantified in available studies.

Medium 🟥 🟥

Arthralgia, Myalgia, Carpal Tunnel Syndrome, and Paresthesia

Joint pain (arthralgia), muscle pain (myalgia), and nerve compression symptoms are the classic dose-limiting complaints of growth hormone-axis stimulation, and they share a mechanism with the fluid retention above: soft-tissue swelling in anatomically confined spaces. Carpal tunnel syndrome (compression of the median nerve where it passes through the wrist, producing numbness, tingling, and weakness in the hand) is the most specific of these. Paresthesia (abnormal tingling or “pins and needles” sensation) in the hands and feet is common enough to be considered expected at higher doses. In a 318,749-person prospective cohort with 11.5 years of follow-up, higher circulating IGF-1 was positively associated with incident carpal tunnel syndrome after correction for multiple testing (a statistical adjustment that raises the bar for significance when many outcomes are examined at once, so that chance findings are filtered out), which is unusually direct epidemiological support for a mechanism otherwise inferred from trials (Papier et al., 2022). These effects are dose-dependent and reverse on dose reduction.

Magnitude: Hazard ratio (HR, a measure of how much a factor multiplies the rate of an event over time) 1.12 per 5 nmol/L higher IGF-1 for carpal tunnel syndrome, 95% CI (confidence interval, the range within which the true value is likely to lie) 1.08–1.16, in 318,749 adults followed for an average of 11.5 years.

Impaired Glucose Tolerance and Rising Fasting Insulin ⚠️ Conflicted

Growth hormone is a counter-regulatory hormone to insulin: it reduces glucose uptake in muscle and fat and increases hepatic glucose output, so sustained elevation should be expected to worsen insulin sensitivity. The trial evidence is genuinely divided: in the 20-week randomized cognition trial, daily GHRH analog raised fasting insulin substantially in the participants with mild cognitive impairment, though not in the healthy participants and not out of the normal range. In the pooled 806-participant tesamorelin phase 3 analysis, no clinically meaningful differences in glucose parameters were seen against placebo at either 26 or 52 weeks, and the pivotal trial similarly found no significant glycaemic differences. The most likely explanation for the discrepancy is that the effect depends on baseline metabolic status and on how much visceral fat is lost — visceral fat reduction improves insulin sensitivity and can offset the direct antagonism. For a lean person with nothing to lose from the visceral depot, only the antagonism remains.

Magnitude: Fasting insulin rose 35% within the normal range over 20 weeks in adults with mild cognitive impairment on daily GHRH analog, while the pooled 806-participant phase 3 tesamorelin data showed no clinically meaningful glucose differences versus placebo through 52 weeks.

Sustained IGF-1 Elevation and Cancer Risk

IGF-1 is a mitogen and an anti-apoptotic signal (it tells cells to divide and not to die), which is exactly the pharmacology one would not choose in the presence of an occult malignancy. Large prospective cohorts consistently link higher circulating IGF-1 to increased incidence of several cancers, and the associations survive Mendelian randomization analysis (a technique that uses inherited genetic variation as a natural experiment to test whether a marker causes an outcome rather than merely tracking it) for prostate cancer, which argues for causality rather than reverse association. In 394,388 cancer-free UK Biobank participants, higher IGF-1 was associated with increased risk of colorectal, breast, prostate, and thyroid cancer (Knuppel et al., 2020). Two caveats cut in opposite directions: the per-unit hazard ratios are small and the follow-up was short, but the observational data describe lifetime variation within the physiological range, whereas this compound produces a sustained pharmacological elevation of a different order. No trial has been long enough or large enough to measure cancer incidence with any GHRH analog.

Magnitude: HR per 5 nmol/L higher IGF-1 of 1.08 (95% CI 1.03–1.13) for colorectal cancer, 1.11 (1.07–1.15) for breast cancer, 1.08 (1.05–1.12) for prostate cancer, and 1.18 (1.01–1.37) for thyroid cancer.

Uncertain Identity, Purity, and Dose of Gray-Market Product

Because no approved CJC-1295 product exists, essentially all material in circulation is sold as a research chemical outside pharmaceutical quality systems. The specific risks are misidentification, underdosing or overdosing relative to the label, bacterial endotoxin, residual synthesis solvents, and incorrect peptide sequences. A documented illustration is the analysis of an unlabelled pharmaceutical preparation seized by Norwegian customs, which mass spectrometry showed to contain a 29-amino-acid peptide consistent with CJC-1295 (Henninge et al., 2010). A second, more pervasive problem is that a large share of product sold as “CJC-1295” is actually Modified GRF 1-29 without the albumin tether — a compound with a half-life measured in minutes rather than days, requiring an entirely different dosing schedule to do anything at all. Clinical reviews of this space treat uncertainty about composition, dose, and stacking as a primary risk in its own right (Dominikowski et al., 2026).

Magnitude: Not quantified in available studies.

Hypersensitivity Reactions

Systemic allergic reactions to the injected peptide — itching, redness, flushing, urticaria (raised itchy welts), and rash arising away from the injection site — are a labelled warning for the only approved compound in this class and sit among its most frequently reported adverse reactions. The mechanism is an immune response to a foreign peptide sequence, and it is tightly linked to antibody formation: in the class trial programme the large majority of participants who had a hypersensitivity reaction were antibody positive. Severity is usually mild, but the labelled instruction is to stop the drug immediately and seek medical attention rather than to treat through it, because a reaction can escalate. With gray-market material the picture is harder to read, since a reaction may be to an endotoxin or a contaminant rather than to the peptide, and no hypersensitivity data of any kind exist for CJC-1295 itself.

Magnitude: Hypersensitivity reactions occurred in 4% of participants treated with the approved GHRH analog across its clinical trial programme, and 85% of those affected were positive for anti-drug antibodies.

Anti-Drug Antibody Formation

Any injected peptide can provoke an immune response, and covalently modifying a person’s own albumin creates a neoantigen (a structure the immune system has never seen), which adds a route to antibody formation that the rest of this class does not have. The class evidence here is substantial rather than theoretical: roughly half of participants treated with the approved GHRH analog developed anti-drug antibodies within 26 weeks, about 60% of those antibodies cross-reacted with the body’s own growth hormone-releasing hormone, and a minority were neutralizing in laboratory assay. The reassuring part of the same dataset is that antibody-positive and antibody-negative participants had comparable visceral fat and IGF-1 responses, so the antibodies did not measurably blunt the drug. What remains unknown for CJC-1295 specifically is whether the albumin conjugate raises that rate, prolongs it, or produces antibodies that cross-react with native albumin, since no immunogenicity data for this compound have been published beyond the short trial durations.

Magnitude: Anti-drug antibodies in 50% of participants at 26 weeks and 47% at 52 weeks with the approved GHRH analog, cross-reacting with the body’s own growth hormone-releasing hormone in about 60% of antibody-positive participants and neutralizing in laboratory assay in 10%, with no measurable loss of effect; no data for CJC-1295.

Low 🟥

Serious Cardiovascular Events ⚠️ Conflicted

The most consequential single safety signal in the history of this compound is the participant death that ended the phase 2 programme, reported as a fatal cardiac event a few hours after an eleventh weekly injection in a trial of people with HIV-associated visceral obesity. The sponsor’s assessment was that the death was unlikely to be drug-related, and no causal mechanism was ever established or published. Against that, the compound is known to cause fluid retention and plasma volume expansion, and the population studied — people on long-term antiretroviral therapy with central adiposity — carries elevated baseline cardiovascular risk. A single event in a trial of this size cannot establish an excess risk, and it equally cannot exclude one; what it does establish is that no controlled cardiovascular safety data for this compound exist and that the programme designed to generate them was never completed.

Magnitude: One fatal cardiac event in the single phase 2 trial (NCT00267527, 120 participants planned, terminated 2006); no controlled estimate of excess cardiovascular risk exists for this compound.

Vasodilatory Symptoms: Flushing, Headache, and Transient Dizziness

Transient facial flushing and a sensation of warmth shortly after injection, headache, and occasional light-headedness are recognized short-term effects of GHRH and its analogs, attributable to direct vasodilatory action of the peptide rather than to the downstream growth hormone rise. They typically occur within minutes to an hour of dosing, are self-limiting, and diminish with repeated exposure. In the CJC-1295 ascending-dose trials these were among the reported adverse effects, described overall as mild and generally of short duration at the doses studied.

Magnitude: Not quantified in available studies.

Worsening of Obstructive Sleep Apnea

Obstructive sleep apnea (repeated collapse of the upper airway during sleep, producing breathing pauses and fragmented rest) is the classic sleep consequence of growth hormone excess, affecting the majority of people with acromegaly (the disease of chronic growth hormone excess) through soft-tissue thickening of the tongue and pharynx, and it carries a labelled warning for recombinant growth hormone. The same two mechanisms behind the fluid retention described above, sodium and water retention plus soft-tissue expansion, apply in miniature to any sustained rise in growth hormone and IGF-1, and both narrow an airway that may already be marginal. No study of CJC-1295 or of any other GHRH analog has measured apnea-hypopnea events, so the concern rests on the acromegaly literature and the growth hormone label rather than on class trial data, which is why it sits at this evidence level rather than higher. It is most relevant precisely where the compound is most used: middle-aged and older adults with central adiposity, in whom undiagnosed apnea is already common and in whom a worsening airway would erode the sleep quality that is among the commonest reasons for taking it.

Magnitude: Not quantified in available studies.

Tachyphylaxis and Attenuated Response Over Time

Tachyphylaxis is a progressive loss of drug effect with continued exposure. The theoretical concern with a continuously acting GHRH signal is somatotroph desensitization or depletion of releasable growth hormone stores. Direct measurement argues against this in the short term: pulsatility was fully preserved a week after a single injection, and animal work showed increased pituitary growth hormone messenger RNA and evidence of somatotroph proliferation rather than exhaustion. Set against that, IGF-1 accumulated rather than declined across repeated doses in the human trials, which is the opposite of tachyphylaxis. The residual uncertainty is entirely about exposure beyond a few weeks, which has never been studied.

Magnitude: Not quantified in available studies.

Gastrointestinal Upset

Nausea, vomiting, dyspepsia (indigestion), and upper abdominal pain are common in the trial programme of the approved compound in this class, though they are not among the effects reported in the CJC-1295 human pharmacology studies. The mechanism is not established, and these complaints were not separated from background gastrointestinal symptoms in the population studied. They are generally mild and self-limiting, and they matter here mainly because they are easy to misattribute to whatever else is being taken alongside. They sit at this evidence level because they come entirely from a daily-dosing schedule in a different population, with nothing measured for the once-weekly exposure this compound produces.

Magnitude: Nausea, vomiting, dyspepsia, and upper abdominal pain each reported in 1–10% of participants in the approved GHRH analog’s trial programme; not quantified for CJC-1295.

Speculative 🟨

Acromegaly-Like Tissue Changes with Chronic Supraphysiological Use

Acromegaly is the disease of chronic growth hormone excess, producing enlargement of the hands, feet, and jaw, thickened soft tissue, cardiomyopathy, hypertension, diabetes, and shortened life expectancy. No case has been attributed to CJC-1295, and the intact negative feedback loop should in principle prevent it, since rising IGF-1 suppresses the pituitary response. The speculative concern is that a covalently albumin-bound agonist cannot be cleared quickly and, if dosed high enough for long enough, could push the axis further and for longer than feedback comfortably controls. The basis is entirely mechanistic and the disease analogy, not any reported case series.

Adverse Effect on Long-Term Mortality Through Sustained Growth Signalling

This is the concern most specific to a longevity-oriented reader and the one least addressed by the peptide literature. Reduced growth hormone and IGF-1 signalling is among the most reproducible life-extending manipulations in model organisms, and in humans, families enriched for exceptional longevity show lower and more tightly controlled growth hormone secretion, while people with congenital IGF-1 deficiency appear substantially protected against cancer and diabetes. If that relationship is causal in humans, then chronically raising the same axis is directionally opposed to the goal, whatever it does to body composition in the short term. No controlled data address this either way — the observation is genetic and epidemiological, the intervention is pharmacological, and no trial of any GHRH analog has run long enough to measure mortality.

Risk-Modifying Factors

Personal or family history of cancer: The single most important risk modifier. Someone with a prior malignancy, a strong family history, or an untreated precursor lesion is deliberately raising a mitogenic signal in a body where an occult clone may already exist. The relevant question is not average population risk but individual baseline probability of harbouring transformed cells.
Baseline insulin resistance and glycaemic status: A person with elevated fasting insulin, raised HbA1c (glycated haemoglobin, a measure of average blood glucose over roughly the preceding three months), or established type 2 diabetes has the least metabolic reserve to absorb growth hormone’s insulin-antagonizing effect and is where the glucose risk concentrates.
Baseline IGF-1 already in the upper range: Someone whose starting IGF-1 sits in the top quartile for their age has the least benefit headroom and reaches the elevation range associated with the cancer and carpal tunnel signals fastest.
Cardiovascular status: Existing coronary artery disease, heart failure, uncontrolled hypertension, or significant valvular disease converts the fluid-retention effect from a nuisance into a hazard, and this is precisely the population in which the trial death occurred.
Renal and hepatic function: Impaired kidney function amplifies sodium and water retention. Impaired liver function alters both albumin turnover — which determines how long the drug persists — and the hepatic IGF-1 response, making the exposure less predictable in either direction.
Sex-based differences: Women appear more prone to the sleep-disrupting effect of GHRH, an effect that is directionally opposite to that seen in men in controlled studies. Fluid retention and carpal tunnel symptoms from growth hormone-axis stimulation are also historically more common in women. Against this, women’s relative hepatic growth hormone resistance means a given dose generates less IGF-1, which attenuates the IGF-1-mediated risks.
Age: Older adults are more susceptible to edema, arthralgia, carpal tunnel syndrome, and glucose intolerance at any given level of growth hormone exposure, while also having higher baseline cardiovascular and oncological risk. The risk-benefit balance therefore shifts unfavourably at exactly the age at which the age-related decline argument for using the compound is strongest.
Genetic variation in growth hormone signalling: Carriers of the exon 3-deleted GHR variant generate a larger IGF-1 response per unit of growth hormone and would be expected to reach the risk-relevant range at a lower dose. Variants in IGF1R that increase receptor signalling would act in the same direction. Neither has been tested prospectively in this context.
Concurrent glucocorticoid use or endogenous cortisol excess: Glucocorticoids compound the glucose and fluid effects while simultaneously blunting the growth hormone response, producing the worst combination of risk without benefit.
Pregnancy, breastfeeding, and adolescence: Growth hormone-axis manipulation in pregnancy has no safety data at all, and in anyone with open epiphyseal growth plates (the cartilage zones near the ends of long bones where lengthwise growth occurs) it carries a direct risk of abnormal skeletal growth.

Key Interactions & Contraindications

Prescription medication interactions:

Glucocorticoids (prednisone, dexamethasone, hydrocortisone) — caution, high clinical relevance: Suppress growth hormone secretion and blunt the pituitary response to GHRH while independently raising blood glucose and promoting fluid retention. Consequence: loss of efficacy plus additive hyperglycaemia (high blood sugar) and edema. Mitigation: suspension of the peptide for the duration of any systemic steroid course, with weekly fasting glucose monitoring if the two overlap.
Somatostatin analogs (octreotide, lanreotide, pasireotide) — absolute pharmacological antagonism: Somatostatin is the physiological brake on growth hormone release and these agents are used to treat acromegaly. Consequence: complete abolition of effect. Mitigation: none available — the combination is pharmacologically self-defeating.
Insulin and insulin secretagogues (glipizide, glyburide, glimepiride) — caution, monitor: Growth hormone-induced insulin resistance can raise insulin requirements. Consequence: loss of glycaemic control, or conversely hypoglycaemia (blood sugar falling too low) if the peptide is stopped abruptly while doses remain elevated. Mitigation: continuous or frequent glucose monitoring for the first 4–6 weeks and again on discontinuation, with dose review by the prescribing clinician.
Oral estrogens (conjugated equine estrogens, oral estradiol) and selective estrogen receptor modulators (raloxifene, tamoxifen) — caution, dose-relevant: First-pass hepatic exposure to oral estrogen blunts liver IGF-1 generation. Consequence: a substantially smaller IGF-1 response at the same dose, which is easily misread as an inactive product. Mitigation: transdermal estrogen avoids first-pass exposure and largely removes the interaction; IGF-1 results are interpreted in light of the route used.
Levothyroxine and thyroid status — monitor: Growth hormone increases peripheral conversion of thyroxine to the active triiodothyronine and can unmask previously subclinical central hypothyroidism. Consequence: shifting thyroid function tests and symptoms of over- or under-replacement. Mitigation: thyroid function measured at baseline and at 12 weeks.
Recombinant human growth hormone (somatropin) — redundant and additive, absolute contraindication in combination: Delivers the same downstream signal by a different route while bypassing feedback control. Consequence: additive risk of edema, arthralgia, glucose intolerance, and acromegaly-like changes with no additional benefit. Mitigation: the two are not combined; where growth hormone deficiency is documented, replacement therapy under endocrine supervision is the route with regulatory approval behind it.
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) — caution, interaction of interpretation rather than pharmacology: GLP-1 receptor agonists are a drug class that mimics glucagon-like peptide-1, an incretin gut hormone, to reduce appetite and improve glucose control. Consequence: substantial concurrent fat loss makes it impossible to attribute any body composition change to the peptide, and the combined caloric deficit can accelerate lean mass loss. Mitigation: separation of the two interventions in time, and tracking of lean mass rather than weight alone.
Antiretroviral therapy (ritonavir, darunavir, dolutegravir, tenofovir) — monitor, no pharmacokinetic interaction expected: Because CJC-1295 is not metabolized by cytochrome P450 enzymes, there is no expected interaction with protease inhibitors (a class of antiviral drugs that block the enzyme HIV uses to assemble new virus particles) or other agents that depend on that system. Consequence: none pharmacokinetically. Mitigation: none required; the relevance is historical, since this was the population in which the terminated trial ran.

Over-the-counter medication interactions:

NSAIDs (non-steroidal anti-inflammatory drugs — ibuprofen, naproxen, diclofenac) — caution, additive: Promote renal sodium and water retention. Consequence: additive edema and blood pressure elevation. Mitigation: chronic daily use avoided during dose escalation, with ankle swelling checked if a short course is unavoidable.
Oral decongestants (pseudoephedrine, phenylephrine) — caution: Raise blood pressure on top of any peptide-related fluid expansion. Consequence: additive hypertension. Mitigation: nasal saline or an intranasal steroid as substitutes, with blood pressure checked if a decongestant is used.
Melatonin — mild, potentiating: Melatonin modestly stimulates nocturnal growth hormone release. Consequence: additive rather than adverse, but it confounds attribution of any sleep or hormone change. Mitigation: the variable held constant across a monitoring cycle.

Supplement interactions, including supplements with additive effects:

MK-677 (ibutamoren) — strongly additive, caution: An orally active growth hormone secretagogue acting at the ghrelin receptor, a completely different receptor from the one this peptide binds. Consequence: markedly amplified growth hormone and IGF-1 output plus MK-677’s own effects on appetite, cortisol, prolactin, and fluid retention, with a correspondingly amplified risk profile. Mitigation: the combination is treated as a substantial dose escalation rather than an additive convenience, with the peptide dose reduced accordingly.
Growth hormone-releasing peptides (ipamorelin, GHRP-2, GHRP-6, hexarelin, tesamorelin, sermorelin) — caution, strongly additive by design: These are the compounds most commonly stacked with CJC-1295, on the correct pharmacological reasoning that ghrelin-receptor agonists and GHRH-receptor agonists act synergistically at the pituitary. Consequence: a supra-additive hormone response, and with GHRP-2, GHRP-6, and hexarelin, additional elevation of prolactin and cortisol that CJC-1295 alone does not produce. Mitigation: ipamorelin is the most selective partner where stacking is used, and prolactin and morning cortisol are measured at baseline and at 12 weeks with the less selective agents.
Arginine, ornithine, glycine, and GABA (gamma-aminobutyric acid, the main inhibitory neurotransmitter) — mildly additive: All are promoted as growth hormone secretagogues; arginine’s effect is real but works by suppressing somatostatin, which is the same brake the peptide is already working against. Consequence: modest additive hormone release and confounded attribution. Mitigation: no dose adjustment needed, but the supplement is held constant during any monitoring period.
Chromium, berberine, and inositol — potentially offsetting, favourable: Insulin-sensitizing supplements work against the one metabolic liability of this mechanism. Consequence: partial offset of the glucose effect. Mitigation: none needed; this is a rational pairing rather than a hazard.
High-dose biotin — monitor, analytical interference rather than pharmacological: Interferes with many immunoassays, including some IGF-1 assays. Consequence: falsely high or low IGF-1 readings that drive wrong dose decisions. Mitigation: biotin stopped 72 hours before any blood draw.

Other intervention interactions:

Caloric restriction and prolonged fasting — caution, mechanistically opposed on IGF-1: Fasting raises growth hormone sharply while lowering IGF-1; this peptide raises both. Consequence: the two push IGF-1 in opposite directions, so combining them makes net exposure unpredictable and undermines the rationale of each. Mitigation: separation of fasting protocols from dosing blocks, so that each can be assessed on its own.
Testosterone replacement therapy — caution, additive on IGF-1: Androgens raise IGF-1 independently and amplify the anabolic response. Consequence: higher combined IGF-1 exposure than either alone, reaching the risk-relevant range at a lower peptide dose. Mitigation: IGF-1 measured with both interventions at steady state rather than assuming the individual effects add predictably.

Populations who should avoid this intervention:

Active malignancy, or any cancer treated within the preceding 5 years — absolute contraindication given the mitogenic mechanism and the IGF-1-cancer associations.
Known or suspected pituitary adenoma, or any history of pituitary tumour — absolute contraindication; chronic GHRH-receptor stimulation drives somatotroph proliferation.
Proliferative or severe non-proliferative diabetic retinopathy (damage to the retinal blood vessels from diabetes, which in the proliferative stage involves the growth of fragile new vessels) — absolute contraindication; IGF-1 is implicated in the growth of those new vessels.
Uncontrolled type 2 diabetes (HbA1c above 8.0%) — avoid until glycaemic control is established, given the direct insulin-antagonist effect.
Heart failure of NYHA Class III or IV (New York Heart Association functional classification, where Class III means marked limitation with ordinary activity and Class IV means symptoms at rest) — avoid, given sodium and water retention.
Recent myocardial infarction (within 90 days), unstable angina, or uncontrolled arrhythmia — avoid, in light of the fluid-volume effect and the unresolved trial death.
Acute critical illness, major surgery, or acute respiratory failure — avoid; growth hormone administration in critical illness increased mortality in a landmark trial, and albumin turnover in critical illness makes exposure unpredictable.
Child-Pugh Class B or C liver disease (a staging system for chronic liver impairment, where Class C is the most severe) — avoid; albumin handling and hepatic IGF-1 generation are both disturbed.
Pregnancy and breastfeeding — avoid; no safety data exist.
Anyone with open epiphyseal growth plates (typically still open under approximately 18–21 years) — avoid, given the direct risk of abnormal skeletal growth.
Competitive athletes subject to anti-doping regulation — the compound is prohibited at all times under the World Anti-Doping Agency’s prohibited list class S2 (peptide hormones and growth factors), and validated detection assays for it exist in both blood and urine.

Risk Mitigation Strategies

Cancer screening completed before starting, not after: Age- and sex-appropriate screening — colonoscopy, mammography or breast imaging, PSA (prostate-specific antigen, a blood marker used to screen for prostate cancer) and a full skin examination — performed before the first dose and repeated on the normal recommended schedule. This mitigates the central risk of raising a mitogenic signal in the presence of an undetected malignancy.
Low starting dose with slow titration: Gray-market schedules commonly begin at a flat 1–2 mg weekly and continue indefinitely, whereas the trial doses of 30–120 µg/kg were given for a few weeks at most, so cumulative exposure soon exceeds anything that has been studied. Protocols starting at 0.5 mg once weekly and increasing by 0.5 mg every 3–4 weeks, and only while IGF-1 remains below target, mitigate the dose-dependent risks: edema, arthralgia, carpal tunnel syndrome, and glucose intolerance.
Titration to an IGF-1 target rather than to a fixed dose: An upper bound set at the age-adjusted reference range — in practice an IGF-1 z-score (how many standard deviations a result sits above or below the average for that age and sex) no higher than +1.5, or roughly 200 ng/mL in most middle-aged adults — with the dose reduced whenever a level exceeds it. This is the most direct mitigation of both the cancer-risk signal and acromegaly-like tissue changes, because it caps exposure at a level the body produces naturally.
Quarterly metabolic monitoring during the first year: Fasting glucose, fasting insulin, and HbA1c at baseline, week 12, and every 3 months thereafter, with a pre-defined stopping rule — discontinuation if HbA1c rises by more than 0.3 percentage points or fasting insulin exceeds 10 µIU/mL. This mitigates the insulin resistance risk before it becomes clinically established.
Weekly self-check for fluid retention: Same-time-of-day body weight plus a visual check of ankles and finger rings during the first 8 weeks. A gain of more than 1.5 kg in a week without a change in intake indicates fluid rather than tissue and triggers a dose reduction. This mitigates edema and the cardiac strain it can impose.
Immediate dose reduction on hand symptoms: Any nocturnal hand numbness, tingling, or grip weakness triggering a 50% dose reduction rather than watchful waiting. This mitigates carpal tunnel syndrome, which resolves readily when caught early and can require surgical release if allowed to persist.
Product verification before the first dose: A batch-specific certificate of analysis showing HPLC (high-performance liquid chromatography, a laboratory technique that separates and quantifies the components of a mixture) purity above 98% and mass spectrometry identity confirmation, with explicit confirmation of whether the product is the drug affinity complex version or the version without it. This mitigates both the contamination risk and the far more common problem of dosing the wrong molecule on the wrong schedule.
Injection site rotation on a fixed pattern: At least four abdominal or thigh sites in rotation, at least 2 cm apart, with fresh needles and alcohol preparation. This mitigates injection-site reactions and lipohypertrophy, the leading cause of discontinuation.
No stacking during the assessment period: The compound run alone for the first 12 weeks before any ghrelin-receptor agonist is added. This mitigates the risk of an amplified and unattributable hormone response, and it is the only way to establish whether an observed effect belongs to this compound at all.
A hard time limit with scheduled reassessment: A defined 12–16 week block with full biomarker reassessment before any continuation. This mitigates the accumulation risk implied by IGF-1 remaining above baseline for up to 28 days after repeated dosing, which means steady-state exposure runs higher than any single-dose measurement suggests.

Therapeutic Protocol

There is no approved protocol for CJC-1295, because there is no approved product. What follows separates what was actually studied in trials from what is used in practice, and identifies who popularized each approach.

The trial protocol (drug affinity complex form): Single subcutaneous doses of 30, 60, 90, or 120 µg/kg, with 30 and 60 µg/kg identified as the best-tolerated. Multiple-dose arms used weekly or every-other-week administration. The terminated phase 2 trial escalated weekly doses across three weeks — 60, 90, then 120 µg/kg in the low arm and 60, 120, then 240 µg/kg in the high arm — then continued for nine further weeks. For a 75 kg adult, 30 µg/kg is approximately 2.25 mg.
The gray-market protocol (drug affinity complex form): Typically a flat 1–2 mg subcutaneously once or twice weekly, often split into two 1 mg doses to smooth the peak. This is a lower per-dose exposure than the trials used for a typical adult, but administered indefinitely rather than for 12 weeks.
The pulsatile protocol (version without the albumin tether): Modified GRF 1-29 at 100 µg subcutaneously one to three times daily, most commonly at bedtime and, if used more than once, before a fasted training session. This schedule is designed to mimic natural pulses rather than to sustain a plateau, and is pharmacologically a different intervention despite usually being sold under the same name.
Competing therapeutic approaches: Conventional endocrinology treats documented adult growth hormone deficiency with recombinant growth hormone under specialist supervision, and treats HIV-associated visceral fat accumulation with tesamorelin, the one GHRH analog with regulatory approval — an approach for which the evidence base is far stronger but the indications far narrower. The integrative and longevity-clinic approach, popularized in the United States largely through the peptide-therapy training programmes associated with William Seeds and the Seeds Scientific Research and Performance group, and through the International Peptide Society, favours secretagogue combinations in people without a diagnosed deficiency. Both of these organizations derive direct revenue from clinician training and from the peptide protocols they endorse, and the professional endocrine societies that oppose the practice are composed of members reimbursed for managing diagnosed pituitary disease; neither position is offered here as the default.
Best time of day: Bedtime, for the pulsatile version, so that the induced pulse coincides with the natural nocturnal surge during slow-wave sleep. For the drug affinity complex version, timing is largely irrelevant to efficacy because the exposure is continuous across the week — the practical argument for evening dosing is only that it puts the transient flushing and headache during sleep.
Single versus split dosing: For the drug affinity complex version, splitting a weekly dose into two half-doses three to four days apart reduces the post-injection peak without changing weekly exposure, and is the more conservative choice for anyone susceptible to fluid retention. For the version without the tether, splitting is mandatory rather than optional — a single daily dose produces one pulse and nothing else.
Half-life and its practical consequence: With a 5.8–8.1 day half-life, steady state is not reached for four to five weeks of weekly dosing, and IGF-1 continues to climb across that period. Judging a dose from a level drawn at week 2 systematically underestimates the eventual exposure, and this is the most common source of unintentional overdosing.
Food and fasting relative to dosing: For the pulsatile version, a high fat or high carbohydrate meal within 2 hours before dosing blunts the growth hormone pulse through raised somatostatin tone and rising insulin; a fasted state of at least 2 hours is standard practice. For the continuous version this consideration largely disappears.
Baseline biomarkers as protocol input: A baseline IGF-1 in the lower third of the age-adjusted range supports a standard starting dose; a baseline already above the age-adjusted mean argues against the intervention entirely. Baseline fasting insulin above 8 µIU/mL argues for a lower starting dose and tighter glucose monitoring.
Sex-based protocol differences: Women on oral estrogen show a blunted IGF-1 response, and protocols address this by switching to transdermal delivery — which restores normal hepatic IGF-1 generation — rather than by escalating the dose to compensate. Given the controlled evidence that GHRH disrupts sleep in women in the opposite direction to men, some protocols move evening dosing to the morning where sleep quality deteriorates.
Age-based protocol differences: For adults over 60, clinic protocols typically halve the standard starting dose and extend the titration interval to 4–6 weeks, because somatotroph responsiveness is lower while susceptibility to edema, joint symptoms, and glucose intolerance is higher. The animal data showing that once-daily dosing was substantially more effective than every-48-or-72-hour dosing indicate that dosing interval matters more than total weekly amount, which argues for smaller, more frequent doses rather than a single large weekly injection in this group.
Genetic polymorphisms influencing dose: Carriers of the exon 3-deleted variant of the growth hormone receptor gene generate more IGF-1 per unit of growth hormone, which implies a slower titration to reach the same IGF-1 target. Variants in the GHRH receptor gene itself would alter the response at the pituitary. None of this is routinely tested, and no dosing algorithm based on it has been validated.
Pre-existing conditions influencing response: Untreated hypothyroidism, chronic glucocorticoid exposure, and obesity all blunt the growth hormone response, so protocols correct them before starting; where they are left uncorrected, a non-response is misread as an inadequate dose and drives escalation into the risk range.

Discontinuation & Cycling

Lifelong versus short-term use: No study of any duration has established what continued use does. The longest human exposure in the published trials was 49 days in the healthy-volunteer programme and 12 weeks in the terminated phase 2 trial. Everything beyond that is extrapolation. The practical position taken in most clinic protocols is defined blocks of 8–16 weeks rather than continuous use, which is a reasonable response to the absence of long-term data rather than a finding in its own right.
Withdrawal effects: There is no physical dependence and no described withdrawal syndrome. What does occur is a return of growth hormone and IGF-1 toward baseline, which people commonly experience as a loss of the sleep quality, recovery, and body composition changes they had attributed to the compound. Because IGF-1 remained above baseline for up to 28 days after multiple doses in the trials, this decline is gradual rather than abrupt.
Tapering protocol: No taper is pharmacologically necessary, and none is possible to improve on: the 5.8–8.1 day half-life means the drug tapers itself over roughly a month after the last dose. For the version without the albumin tether, the same logic does not apply — its effect ends within hours — but there is still no rebound to taper against. The one situation warranting a deliberate step-down is concurrent diabetes medication, where the return of insulin sensitivity on discontinuation can produce hypoglycaemia if insulin or secretagogue doses are not reduced in parallel.
Whether cycling maintains efficacy: The usual rationale for cycling — that continuous stimulation exhausts or desensitizes the pituitary — is not supported by the direct measurements available. Pulsatility was fully preserved a week after a single injection, IGF-1 accumulated rather than faded across repeated doses, and animal work showed somatotroph proliferation and increased growth hormone messenger RNA rather than depletion. The better argument for cycling is not preserved efficacy but limited cumulative exposure: shorter blocks cap total lifetime IGF-1 elevation, which is the exposure the cancer and mortality concerns attach to.
A defensible cycling structure: Where cycling is used, 12 weeks on followed by 4–6 weeks off, with a full biomarker panel drawn at the end of each on-block and again after the washout, allows the effect and its reversibility to be observed rather than assumed. This is a pragmatic structure, not an evidence-based one, and no comparison of cycled against continuous dosing has ever been performed with any GHRH analog.

Sourcing and Quality

No pharmaceutical-grade product exists: CJC-1295 has never been approved by any regulator, so there is no reference product, no pharmacopoeial monograph, and no manufacturer subject to routine inspection. This is the fundamental sourcing fact and it cannot be worked around, only managed.
The compounding pharmacy route is largely closed in the United States: CJC-1295 was nominated for the list of bulk drug substances usable in pharmacy compounding and was placed in Category 2 — substances the FDA (US Food and Drug Administration) identified as raising significant safety concerns — in 2023. Its status has since been revised as nominations were withdrawn and the substance was referred for advisory committee review, and it has remained outside the category of substances that may be routinely compounded. The practical consequence is that a legitimate compounding pharmacy in the United States — whether a 503A pharmacy compounding for individual prescriptions or a 503B outsourcing facility compounding in bulk — generally cannot supply it, and a US pharmacy offering it is operating on an unclear regulatory basis.
Identity of the molecule actually in the vial: The most common and most consequential quality problem is not contamination but identity. A large share of product labelled “CJC-1295” contains Modified GRF 1-29 without the albumin-binding modification — a compound with a half-life of about 30 minutes rather than about a week. Dosed on a weekly schedule it will do essentially nothing, and dosed on a daily schedule the true drug affinity complex version will accumulate to several times the intended exposure. Vendors sometimes distinguish these as “with DAC” and “no DAC”, and sometimes do not.
Batch-specific certificate of analysis: A useful certificate names the specific lot, reports HPLC purity (ideally above 98%), confirms molecular identity by mass spectrometry against the expected mass, and reports water content and residual solvent. A generic certificate not tied to the lot in hand, or one showing only purity without an identity confirmation, is close to worthless. Third-party analytical laboratories that will test a submitted vial independently of the seller exist and are the only genuinely independent check available.
Endotoxin and sterility matter more than purity: For an injected product, bacterial endotoxin content is the specification most relevant to acute harm and the one most often omitted. Peptides synthesized without downstream endotoxin control can cause fever and systemic inflammatory reactions even at high chemical purity.
Formulation, reconstitution, and storage: Product is supplied as a lyophilized (freeze-dried) powder, which is stable at room temperature for shipping but degrades unless refrigerated on receipt and protected from light. Reconstitution with bacteriostatic water — sterile water containing 0.9% benzyl alcohol — permits multi-dose use over roughly four weeks refrigerated; plain sterile water permits only single-day use because it contains no preservative. Vigorous shaking denatures the peptide, so swirling to dissolve is the standard handling practice.
Reputable channels, with a caveat: Outside the United States, some regulated compounding pharmacies in jurisdictions with different bulk-substance rules will prepare the peptide on prescription, and these are materially more reliable than research-chemical vendors because they are subject to pharmacy inspection. The peptide-therapy clinic channel sits in between: clinics often source from the same compounders but have a direct financial interest in the volume they dispense, which is worth weighing against the convenience they offer.

Practical Considerations

Time to effect: IGF-1 begins rising within 24–48 hours of the first injection and peaks within the first week, but steady state is not reached for four to five weeks of weekly dosing. Subjective changes in sleep and recovery, where they occur, are reported within the first two weeks. Measurable body composition change, based entirely on the class data, took 12–26 weeks in trials, and no shorter timeline is credible.
Common pitfalls: Dosing the version without the albumin tether on a weekly schedule, which produces no sustained effect at all, is the most frequent error. Escalating the dose based on a level drawn before steady state is the second, and it is the main route to unintentional overexposure. Others include stacking with a ghrelin-receptor agonist from day one, which makes attribution impossible; never measuring IGF-1, which removes the only feedback signal available; interpreting a rapid two-kilogram weight gain as muscle when it is water; and injecting into the same site repeatedly until lipohypertrophy develops.
Regulatory status: CJC-1295 is not approved as a medicine by the FDA, the European Medicines Agency, or any other major regulator, and there is therefore no such thing as legitimate off-label use — off-label use presupposes an approved product. It is sold in the United States as a research chemical labelled “not for human consumption”, a designation that carries no quality obligation whatsoever. It sits outside the substances that may be routinely used in pharmacy compounding. It is prohibited at all times in sport under the World Anti-Doping Agency’s class S2, and validated detection methods for GHRH analogs in blood and urine have been published and deployed by anti-doping laboratories (Memdouh et al., 2021).
Cost and accessibility: Gray-market vials are inexpensive relative to the alternatives — typically a modest per-month cost for a 5 mg vial — while the one approved compound in the class has historically carried a list price in the thousands of dollars per month, and recombinant growth hormone is comparable or higher. This gap has a structural consequence worth naming: institutional payers, whether insurers or national health systems, have a strong systematic incentive to restrict growth hormone-axis therapy to the narrow approved indications, and that incentive shapes which trials get funded and how guidelines are written just as surely as manufacturers’ incentives shape the trials that do get run. The corresponding incentive on the other side belongs to clinics and suppliers, whose revenue depends on dispensing volume. Neither incentive tells us whether the compound works.
Practical burden: Subcutaneous injection once or twice weekly is among the lowest-burden protocols in this space, and is the main practical advantage of the drug affinity complex form over daily alternatives. Against that, the compound requires refrigeration, reconstitution, sharps disposal, and quarterly blood work to be used responsibly, and the blood work is often the larger recurring cost.

Interaction with Foundational Habits

Sleep: The interaction is bidirectional and sex-dependent. The largest natural growth hormone pulse occurs during slow-wave sleep, so poor sleep independently suppresses the axis this compound is trying to raise; someone sleeping five hours a night is working against the intervention. In the other direction, GHRH is itself a sleep-regulating signal — it increased non-REM sleep after sleep deprivation in a mixed-sex randomized study, while in healthy young women it reduced both deep sleep and REM sleep. Practical consequences: sleep is a larger lever on growth hormone than the peptide is; evening dosing suits those whose sleep improves and morning dosing those whose sleep worsens; and alcohol within three hours of bed suppresses slow-wave sleep and blunts the nocturnal pulse regardless of what is injected.
Nutrition: The interaction is blunting and depends on which version of the compound is used. Elevated insulin and free fatty acids both suppress growth hormone release, so a high-carbohydrate or high-fat meal shortly before a pulsatile dose measurably reduces the resulting pulse; a 2-hour fasted window before dosing is the standard practical response, and it matters for the version without the albumin tether far more than for the version with it. Adequate protein intake — around 1.6 g per kilogram of body weight daily — is a precondition rather than an interaction, because IGF-1 signalling cannot build tissue from an inadequate substrate supply. Obesity independently suppresses the growth hormone response, so reducing body fat by other means increases what this mechanism can deliver. The peptide itself causes no nutrient depletion.
Exercise: The interaction is potentiating but partly redundant. Resistance training and high-intensity intervals are among the strongest physiological stimuli to growth hormone release, acting through the same pituitary by a different upstream route. The important qualification is that exercise-induced growth hormone pulses are large and free, which makes a substantial part of the peptide’s proposed benefit redundant in someone already training hard. Practical consequences: the most defensible timing keeps the peptide away from the immediate post-exercise window rather than stacking two stimuli, placing a pulsatile dose on rest days or at night. A phase 2 trial is currently testing a GHRH analog specifically as an addition to exercise for physical function, which is the right question and has not yet been answered.
Stress management: The interaction is directly opposing. Cortisol and somatostatin are the two brakes on the growth hormone axis, and chronic psychological stress raises both. High cortisol blunts the pituitary response to GHRH, worsens the glucose effect, and adds to fluid retention, so an unmanaged stress load reduces benefit and increases risk simultaneously. The peptide’s own effect on stress hormones differs by sex — GHRH suppressed cortisol in men in controlled sleep studies but raised adrenocorticotropic hormone and cortisol in some samples of women — which is a further reason for measuring morning cortisol at baseline rather than assuming a direction. Practical consequences: the interventions that lower cortisol — consistent sleep timing, aerobic activity below threshold, and deliberate downregulation practices — raise the ceiling on what this mechanism can achieve.

Monitoring Protocol & Defining Success

Because there is no approved indication and no validated efficacy endpoint, monitoring serves two purposes: confirming the compound is doing what it is supposed to do at the hormone level, and catching the dose-dependent harms early. Baseline testing is the foundation of both — a full panel drawn before the first dose is what makes everything afterwards interpretable, because a rise in IGF-1 without a pre-treatment value cannot be assessed and there is no way to reconstruct it later. The baseline panel covers every marker in the table below.

Ongoing monitoring cadence: the core panel — IGF-1, fasting glucose, fasting insulin, and HbA1c — is repeated at week 6 and week 12, then every 3 months during continued use, and once more 4 weeks after any discontinuation. The full panel, including lipids, thyroid function, prolactin, and cancer screening markers, is repeated at 6 and 12 months. Blood pressure and body weight are checked weekly for the first 8 weeks and monthly thereafter, and body composition imaging at baseline and 6 months.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
IGF-1	Age-adjusted z-score 0 to +1.5; roughly 150–200 ng/mL in most adults aged 40–65	The direct output of the mechanism and the titration target	Conventional adult reference ranges are wide (roughly 50–300 ng/mL) and age-stratified, so a raw value is far less informative than a z-score. High-dose biotin is stopped 72 hours before the draw. No fasting required; drawn at a consistent time of day
IGFBP-3	Mid-reference range, with a normal IGF-1 to IGFBP-3 molar ratio	Distinguishes a true rise in bioavailable growth factor from a rise in bound, inactive hormone	IGFBP-3 is insulin-like growth factor binding protein 3, the carrier protein that holds most circulating IGF-1 in an inactive form. Best paired with IGF-1 in the same draw; a rising IGF-1 with a flat IGFBP-3 indicates a larger free-hormone increase than IGF-1 alone suggests
Fasting glucose	75–86 mg/dL	The first place growth hormone’s insulin-antagonist effect appears	Conventional range extends to 99 mg/dL, which is well above the level at which risk begins to rise. Requires a 10–12 hour fast and a morning draw
Fasting insulin	Below 5 µIU/mL	More sensitive than glucose to early insulin resistance, and the earliest warning of the main metabolic risk	Conventional laboratories often report anything up to 25 µIU/mL as normal, which conceals substantial dysfunction. Must be drawn fasting and paired with glucose to be interpretable
HOMA-IR	Below 1.0	Single number summarizing the glucose-insulin risk, easy to track across visits	HOMA-IR is the homeostatic model assessment of insulin resistance, a calculation that combines fasting glucose and fasting insulin into one index. Calculated rather than measured, so it needs both fasting values from the same draw. Conventional thresholds for concern sit around 2.5
HbA1c	4.8–5.3%	Confirms whether a rise in fasting values represents a real shift in average glucose	Conventional threshold for prediabetes is 5.7%, which is a late signal. Not affected by fasting state; falsely low in anaemia and in haemoglobin variants
Lipid panel with ApoB	ApoB below 80 mg/dL; triglycerides below 80 mg/dL	Tracks the one consistently favourable metabolic effect seen in the class trials	ApoB is apolipoprotein B, the structural protein carried by every artery-damaging lipoprotein particle and a better risk marker than LDL (low-density lipoprotein) cholesterol. ApoB requires no fasting; triglycerides do. Conventional reporting emphasizes LDL cholesterol, which can be normal while particle count is high
hs-CRP	Below 0.5 mg/L	Visceral fat reduction should lower it; a rise suggests an inflammatory response to the injections or the product	hs-CRP is high-sensitivity C-reactive protein, a blood marker of low-grade inflammation. Conventional cardiovascular risk banding calls below 1.0 mg/L low and above 3.0 mg/L high, so the conventional “acceptable” band extends well above this functional target. Invalid within 2 weeks of any infection or intense unaccustomed exercise; a single high value is repeated rather than interpreted
PSA — men only	Below 1.0 ng/mL under age 60, with rate of change more informative than the absolute value	Directly addresses the prostate cancer signal associated with elevated IGF-1	Conventional action threshold is 4.0 ng/mL, which is a screening rather than a monitoring threshold. Values are transiently elevated within 48 hours of ejaculation or cycling
TSH with free T4	TSH 0.5–2.0 mIU/L	Growth hormone alters thyroid hormone conversion and can unmask underlying hypothyroidism	TSH is thyroid stimulating hormone, the pituitary signal that drives the thyroid; free T4 is free thyroxine, the unbound fraction of the main thyroid hormone. Conventional TSH range extends to about 4.5 mIU/L. Drawn in the morning, since TSH has a pronounced daily rhythm
Prolactin	Within the laboratory reference range	Relevant only when stacking with a ghrelin-receptor agonist, which can raise it; this compound alone does not	Drawn at least 1 hour after waking; nipple stimulation and a strenuous session beforehand both raise it transiently
Morning cortisol	10–18 µg/dL at 8 am	Establishes whether stress-axis activity is blunting the response, and catches the sex-divergent cortisol effect	Conventional 8 am reference ranges are considerably wider, typically about 5–25 µg/dL, so a mid-range conventional result can still sit outside this target. Must be drawn between 7 and 9 am to be interpretable; a random afternoon value is not usable
Blood pressure	Below 120/80 mmHg	The most accessible early indicator of fluid retention	Measured seated after 5 minutes’ rest, same arm, same time of day. A rise of 5–10 mmHg systolic within weeks of a dose increase points to volume expansion
DEXA body composition scan	Visceral fat below 100 cm² with stable or increasing lean mass	The only way to distinguish fat loss from fluid shifts and from lean tissue change	DEXA is dual-energy X-ray absorptiometry, a low-dose scan that separates fat, lean, and bone mass. Baseline and 6-month intervals only — it cannot resolve changes over shorter periods. Same machine each time, since measurement error between devices exceeds the effect being tracked

Qualitative markers:

Sleep quality and depth: Time to fall asleep, night wakings, and whether sleep feels restorative — tracked with a wearable if one is already in use, since the effect can go in either direction and self-report alone is unreliable. New or louder snoring and any witnessed breathing pauses are noted separately, because airway narrowing is the specific sleep hazard of this mechanism.
Recovery between training sessions: Days of residual soreness after a hard session, and whether training capacity is maintained across a week.
Joint comfort and hand symptoms: Specifically, any new morning stiffness, joint aching, or nocturnal hand numbness, which are early warnings rather than incidental complaints.
Ring and shoe fit: A simple, sensitive daily check on fluid retention that is more reliable than the scale.
Skin texture and healing speed: Frequently reported subjectively and easy to track photographically, though the most likely to reflect expectation.
Energy and cognitive clarity: Consistency of afternoon energy and subjective sharpness, noting that these are also the markers most sensitive to the sleep changes above rather than to any direct effect.

Defining success: a meaningful result is an IGF-1 rise into the upper half of the age-adjusted range without a deterioration in fasting insulin, HbA1c, or blood pressure, accompanied by a measurable reduction in visceral fat on a repeat scan at 6 months. An IGF-1 rise without any change in body composition, or a body composition change accompanied by rising fasting insulin, is not a success — it is exposure to the risks without the benefit.

Emerging Research

No active trials of CJC-1295 anywhere: The only interventional trial ever registered for this compound, NCT00267527 — a multicentre, randomized, placebo-controlled, double-blind phase 2 study of 12 weeks of dosing in HIV-associated visceral obesity, with 120 participants planned — was terminated in 2006 and no results were posted. No sponsor has registered a trial since. Its evidence base is therefore not merely thin but closed: no new primary data on CJC-1295 itself are being generated anywhere.
Could strengthen — physical function: NCT06554717, a phase 2 trial at Massachusetts General Hospital enrolling 100 participants, is testing tesamorelin as an addition to exercise for physical function in people ageing with HIV, with change in repeated chair stand time as the primary endpoint and frailty, abdominal obesity, and aging among the listed conditions. This is the first trial in this class to take a functional aging endpoint rather than a body composition surrogate, and its result is directly relevant to whether the mechanism does anything a longevity-focused reader would value.
Could strengthen — tissue regeneration: NCT03150511, a phase 2 trial at Johns Hopkins University with 36 participants, is testing tesamorelin for functional recovery after peripheral nerve injury, using a three-point chuck pinch test as the primary endpoint. A positive result would be the first controlled human support for the tissue-repair claims that currently rest on mechanism alone.
Class evidence on cognition: A completed phase 1 study, NCT02553603 at the University of Texas Medical Branch, examined the effect of GHRH on cognitive function in 22 participants spanning normal cognition to mild cognitive impairment. It follows the larger randomized trial that found a favourable cognitive effect driven by executive function (Baker et al., 2012). Whether that finding replicates in an adequately powered trial is the open question, and a failure to replicate would remove one of the more attractive items in the benefit column.
Could weaken — IGF-1 and cancer: Outcome-wide analyses in large prospective cohorts continue to accumulate, with higher circulating IGF-1 associated with increased incidence of colorectal, breast, prostate, and thyroid cancer in 394,388 participants (Knuppel et al., 2020), and with carpal tunnel syndrome across 25 non-cancer conditions in 318,749 participants (Papier et al., 2022). Further work using inherited genetic variation as a natural experiment is the development most likely to change the interpretation, because it can distinguish causal effects from reverse association in a way that observational follow-up cannot.
Could weaken — the longevity axis itself: The genetic and cohort literature on attenuated growth hormone signalling and exceptional human longevity continues to expand, and it points in the opposite direction to everything this compound does. Lower IGF-1 predicted longer survival among nonagenarian women and among people with a cancer history (Milman et al., 2014), and a 22-year follow-up of people with inherited growth hormone receptor deficiency recorded one non-lethal malignancy and no diabetes against 17% and 5% in controls (Guevara-Aguirre et al., 2011). Any well-powered prospective work linking sustained pharmacological IGF-1 elevation to mortality would be decisive against the intervention; none is currently registered, which is itself informative about where research funding flows.
Detection and prevalence research: Analytical chemistry for GHRH analogs has advanced considerably, with validated immunoaffinity and mass spectrometry assays for blood and urine now deployed in anti-doping laboratories (Memdouh et al., 2021). The practical consequence is twofold: detection windows for this compound are long because of its albumin binding, and better assays will for the first time allow real prevalence of use to be estimated rather than inferred from forum activity.
Clinical framework literature: A growing narrative-review literature is attempting to give clinicians a way to interpret symptoms and laboratory abnormalities in patients who are already self-administering these compounds, stratifying peptides by evidence tier from randomized trial data down to complete absence of human studies (Dominikowski et al., 2026; Renke & Chinellato, 2026). This is not new evidence about the compound, but it changes the practical environment: a person using it is now more likely to encounter a clinician who can interpret an unexplained IGF-1 elevation rather than dismiss it.

Conclusion

CJC-1295 is a manufactured version of the brain signal that tells the pituitary gland to release growth hormone, altered so that one injection keeps that signal switched on for days. The human evidence shows clearly that it does exactly this: growth hormone and its downstream messenger rise substantially and stay elevated for over a week. Far less clear is whether raising those hormones in a healthy adult produces the outcomes people seek. The changes in belly fat, liver fat, blood fats, thinking, and sleep commonly attributed to it come almost entirely from studies of related compounds, and no completed trial has measured body composition or long-term health outcomes with CJC-1295 itself.

The safety picture carries the same gap. Short trials found the injections generally tolerated, with reactions at the injection site, flushing, and fluid retention the most common complaints. Development stopped after a death in a mid-stage trial that was never fully explained, and the long-term consequences of holding growth signalling high — including its uneasy relationship with cancer risk and with the lower hormone levels seen in unusually long-lived people — have not been measured.

Much of the underlying evidence was generated by the companies that owned these compounds, and the strongest commercial interest today belongs to the clinics and suppliers of an unapproved product, while the countervailing professional bodies have interests of their own. Compounding this, the material sold under this name is frequently not the molecule described in the published trials.

Top - Benefits - Risks - Protocol

CJC-1295 for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Sustained Elevation of Growth Hormone and IGF-1

Medium 🟩 🟩

Reduction in Visceral Abdominal Fat

Improvement in Triglycerides and Cholesterol Ratios

Reduction in Liver Fat

Low 🟩

Reduction in Total Body Fat with Preserved Lean Mass

Improved Executive Function in Older Adults

Enhanced Deep Sleep ⚠️ Conflicted

Speculative 🟨

Accelerated Soft-Tissue and Tendon Repair

Peripheral Nerve Regeneration

Improved Skin Thickness and Collagen Density

Increased Bone Mineral Density

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Reactions

Fluid Retention and Peripheral Edema

Medium 🟥 🟥

Arthralgia, Myalgia, Carpal Tunnel Syndrome, and Paresthesia

Impaired Glucose Tolerance and Rising Fasting Insulin ⚠️ Conflicted

Sustained IGF-1 Elevation and Cancer Risk

Uncertain Identity, Purity, and Dose of Gray-Market Product

Hypersensitivity Reactions

Anti-Drug Antibody Formation

Low 🟥

Serious Cardiovascular Events ⚠️ Conflicted

Vasodilatory Symptoms: Flushing, Headache, and Transient Dizziness

Worsening of Obstructive Sleep Apnea

Tachyphylaxis and Attenuated Response Over Time

Gastrointestinal Upset

Speculative 🟨

Acromegaly-Like Tissue Changes with Chronic Supraphysiological Use

Adverse Effect on Long-Term Mortality Through Sustained Growth Signalling

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion